Alnylam Presents Phase I Clinical Drug Trial Data at ASH 2016
 Note: The following is an excerpt from a press release from Alnylam Pharmaceuticals, Inc. regarding news from their recent presentation at the American Society of Hematology (ASH) Annual Meeting. The original article can be read in its entirety here.______________________________________________________________________________Alnylam Pharmaceuticals, Inc. presented data from the phase 1 study of fitusiran at the ASH meeting. The […]
Octapharma Announces Two Hemophilia A Clinical Trials Utilizing Wilate
The following is excerpted from a press release from Octapharma USA. Read the press release in it’s entirety here. Octapharma USA has announced that WILATE®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection will be utilized for two important clinical trials for hemophilia A launching in December.Octapharma USA will fund […]
Prescription Benefit Program Changes for Recombinant Clotting Factor Product
It has come to our attention that Helixate FS, a recombinant clotting factor product sold and distributed by CSL Behring, is being removed from prescription benefit programs for a limited number of patients using CVS/Caremark effective January 1, 2017. Patients currently using Helixate FS who have the “Advanced Control Formulary” plan with CVS/Caremark will have the option […]
PPTA Releases Updated Statement on Zika
The following is a summary of a statement released by the Plasma Protein Therapeutics Association (PPTA). To read the PPTA statement in full, click HERE.On September 8, 2016, PPTA issued an updated news release regarding the Zika virus (ZIKV) and plasma protein therapies. In the release, PPTA notes that: ZIKV is in a family of (lipid-enveloped) viruses that is highly […]
Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX
The following is excerpted from a press release from PRNewswire. Read the press release in it’s entirety here. Sangamo BioSciences, Inc. announced earlier this week that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-FIX, the company’s zinc finger nuclease (ZFN)-mediated genome editing product candidate for the treatment of hemophilia B. Sangamo […]
Baxalta Sponsors 63 Students in 2016-17
Baxalta, now part of Shire, has awarded scholarships to 63 students from 13 states, further adding to the list of recipients of its Education Advantage scholarship program. For the seventh consecutive year, Baxalta US Inc. is helping eligible students with a bleeding disorder offset the costs of higher education, advance their careers, and pursue their […]
Voluntary Recalls Issued for Additional Lots of Kogenate FS Recombinant Clotting Factor Product
Bayer has announced a voluntary recall of additional lots of Kogenate FS with vial adapter. This is an update to the recall that was issued on July 25, 2016. All lot numbers affected by the July 25, 2016 recall and August 10, 2016 extension are: Product Lot Number Expiration Date Kogenate FS 250 IU Vial Adapter 270RV8X 12/19/2017 […]
First FDA-Approved Recombinant von Willebrand Factor, Vonvendi, Now Available for von Willebrand Disease
The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it’s entirety here.Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now available […]
Biogen Names New Spin Off, Bioverativ; Aiming for Early 2017 Launch
The following is an excerpt from FierceBiotech.com To read the article in full, click here.Biogen previously announced its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new company will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market. It […]
Shire Discontinues Hemophilia Gene Therapy Drug Development
The following is an excerpt from xconomy.com. To read the article in full, click here.On a conference call Tuesday, Shire CEO Flemming Ornskov said that the Dublin and Lexington, MA, company has discontinued development of BAX 335, an experimental gene therapy for hemophilia B. Prior to the merger of Baxalta and Shire, Baxalta had indicated plans to […]
English 
Español de Puerto Rico